For more updates follow
To get global pharma news updates in whatsapp please
Showing posts with label JOBS. Show all posts
Showing posts with label JOBS. Show all posts
Tuesday 26 October 2021
BIOCON PHARMA LTD WALK IN INTERVIEW FOR PRODUCTION ON 31st OCTOBER, 2021@ GOA
HETERO DRUGS LTD WALK IN INTERVIEW FOR PRODUCTION & QC ON 31 st, OCTOBER, 2021 @ VIZAG
ABOUT COMPANY :
Hetero is a globally renowned vertically integrated pharmaceutical player engaged in research and development, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Backed by 27+ years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world.
Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, which has been approved by top pharma regulatory bodies of the world. Our portfolio includes 300+ products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology etc. Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide.
Over the years, Hetero has established its strong leadership in ARVs and Antiviral therapies and caters to 40% of existing global demand for Anti-Retroviral (ARV) APIs and Finished Dosage Forms (FDFs) used in HIV/AIDS treatment.
A track record of responding to Global Public Health Emergencies
The highlight of Hetero’s 27+ years of existence has been its responsive actions to mitigate pandemics and life-threatening diseases afflicting communities across the world. By partnering with innovators for developing Oseltamivir to fight against Swine Flu Pandemic to enabling access to affordable Hepatitis C medicines in underdeveloped countries, Hetero has always endeavoured to do its bit at times of global health crises and save precious lives.
Since the onset of the Covid-19 pandemic, Hetero has been proactive in responding to the various challenges surrounding it. It has been the first company to launch the licensed version of generic Remdesivir under the brand name ‘Covifor’ in India for treating severely infected patients and followed it up with Favipiravir (Favivir) to provide succor to those affected by mild and moderate symptoms. As of today, the company is among the largest manufacturers of Remdesivir globally.
Illustrating its continuing commitment to play its part in the global fight against the pandemic, Hetero has entered into an agreement with the Russian Direct Investment Fund (RDIF) as a manufacturing partner for producing 100 million doses of the Sputnik V vaccine per year. This development also showcases Hetero’s enduring spirit of collaboration and penchant for contributing to global health and well-being.
For more updates follow
To get global pharma news updates in whatsapp please
AUROBINDO PHARMA LTD HIRING CANDIDATES FOR NASAL PRODUCTION @ NAIDUPETA , NELLORE
ABOUT COMPANY :
Founded in 1986 by Mr. P. V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry.
Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and anti-biotics, among others.
VACANCY DETAILS :
We have an urgent requirement for Nasal Production Technical Assistants @ APL Health Care Limited Unit 4- Naidupet Andhra Pradesh.
Requirement Areas:
Nasal Manufacturing
Nasal Filling
Nasal Packing
Education: ITI / Diploma
Experience:5 - 9 Yrs of relevant experience in Nasal Formulations
Interested candidates send their resumes to pavani.dudi@aurobindo.com
For more updates follow
To get global pharma news updates in whatsapp please
IPCA LABORATORIES LTD WALK IN INTERVIEW ON 31st, OCTOBER, 2021 @ INDORE, M.P
ABOUT COMPANY :
A consumer-led global pharmaceutical company, creating healthy doses of life since 1949.
When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti.
This, is how Ipca works.
For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments.
Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others.
Taking the industry forward
- One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally
- 15 APIs & 11 Formulations manufacturing facility across the globe
- Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy in India
- 4 formulations rank amongst the top 300 brands of Indian Pharmaceutical Market as per IQVIA May 2020
For more updates follow
To get global pharma news updates in whatsapp please
Monday 25 October 2021
MULTIPLE DEPARTMENT (ENGINEERING, STORES, EHS) VACANCY IN HETERO DRUGS LTD @ VIZAG
ABOUT COMPANY :
Hetero is a globally renowned vertically integrated pharmaceutical player engaged in research and development, manufacturing, and marketing of high-quality chemical and biologic medicines across diverse therapeutic areas. Backed by 27+ years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Global Generics, Biosimilars and Custom Pharmaceutical Services. The company is among the largest producers of Active Pharmaceutical Ingredients (APIs) in the world.
Hetero has 36 state-of-the-art manufacturing facilities strategically located worldwide, which has been approved by top pharma regulatory bodies of the world. Our portfolio includes 300+ products encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology etc. Hetero has a strong global presence in over 126 countries and focusses on making affordable medicines accessible to patients worldwide.
Over the years, Hetero has established its strong leadership in ARVs and Antiviral therapies and caters to 40% of existing global demand for Anti-Retroviral (ARV) APIs and Finished Dosage Forms (FDFs) used in HIV/AIDS treatment.
A track record of responding to Global Public Health Emergencies
The highlight of Hetero’s 27+ years of existence has been its responsive actions to mitigate pandemics and life-threatening diseases afflicting communities across the world. By partnering with innovators for developing Oseltamivir to fight against Swine Flu Pandemic to enabling access to affordable Hepatitis C medicines in underdeveloped countries, Hetero has always endeavoured to do its bit at times of global health crises and save precious lives.
Since the onset of the Covid-19 pandemic, Hetero has been proactive in responding to the various challenges surrounding it. It has been the first company to launch the licensed version of generic Remdesivir under the brand name ‘Covifor’ in India for treating severely infected patients and followed it up with Favipiravir (Favivir) to provide succor to those affected by mild and moderate symptoms. As of today, the company is among the largest manufacturers of Remdesivir globally.
Illustrating its continuing commitment to play its part in the global fight against the pandemic, Hetero has entered into an agreement with the Russian Direct Investment Fund (RDIF) as a manufacturing partner for producing 100 million doses of the Sputnik V vaccine per year. This development also showcases Hetero’s enduring spirit of collaboration and penchant for contributing to global health and well-being.
Dear Team,
Greetings from Hetero Drugs
We are looking for the following positions immediately for API Bulk drug unit located in Nakkapally, Vizag.
1. Head - EHS
Experience - 20+yrs with specialisation in Industrial safety.
2. Head - Mechanical Maintenance
Qualification - B. Tech - Mech ( Regular)
Experience - 18-25yrs
3. Manager - Electrical Maintenance
Qualification - B. Tech - Electrical ( Regular)
Experience: 12 -18 yrs
4. Manager - IPQA (API)
Qualification - M. Sc Chemistry ( Regular)
Experience - 10 to 15 yrs
5. DGM / AGM - Utility maintenance
Qualification - B. Tech - Mech ( Regular)
Experience- 20+ yrs
6. Head - Warehouse
Experience - 20+ yrs
7. Manager - TSD / Technical Services
Qualification - B. Tech - Chemical ( Regular)
Experience- 10 - 15 yrs
Interested professionals, please share your cv to
For more updates follow
To get global pharma news updates in whatsapp please
Friday 17 September 2021
OPTIMUS PHARMA LTD WALK IN INTERVIEW FOR PRODUCTION ON 18th, SEPTEMBER, 2021 @ VIZAG
ABOUT COMPANY :
Optimus was established in the year 2004 as custom synthesis
laboratory by a team of Technocrats. It is one of the fastest growing Manufacturer
in Active Pharmaceutical Ingredients (APIs) and Finished dosages.
We expanded into global markets and started filing DMFs for both APIs and Intermediates with various Regulatory agencies.
Optimus Research Center for API & Formulations was set-up as a centralized Research and Development center to focus on Generic product developments suitable for regulated markets.
Optimus Pharma is an integrated pharmaceutical organization engaged in manufacturing of Solid Oral and semisolid formulations.
We have dedicated API manufacturing plants and R&D Centres with a team of Scientists who had a passion towards chemistry and to ensure a better healthcare to everyone.
We help our customers serve global markets with technology based, innovative, cost effective & consumer friendly products of the highest quality.
In the journey of more than a decade Optimus developed many molecules and have emerged as one of the reputed manufacturing company in the industry.
The Optimus group today employs directly about 950 people and provides indirect employment to about 600 across the group. The group has well qualified professionals from all fields and heading the various functional verticals of the Optimus Corporate Group.
For more updates follow
To get global pharma news updates in whatsapp please
GRANULES INDIA LTD WALK IN INTERVIEW FOR FRESHERS ON 18th, SEPTEMBER, 2021 @ HYDERABAD
ABOUT COMPANY :
Granules India Ltd. is a vertically integrated pharmaceutical company, headquartered in Hyderabad, India. We manufacture Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs), distributed to quality conscious customers in both regulated and semi-regulated markets. We are dedicated to excellence in manufacturing, quality and customer service.
As Granules stands today, our business is bucketed into three areas; the Core business which comprises our ‘core molecules- Paracetamol, Ibuprofen, Metformin, Guaifenesin and Methocarbamol; the Emerging business that focuses on manufacturing APIs with a focus on vertical integration.
For more updates follow
To get global pharma news updates in whatsapp please
Monday 2 August 2021
JODAS EXPOIM PVT LTD WALK IN INTERVIEWFOR FRESHERS (M.PHARMACY/ B.PHARMACY/ M.Sc) ON 4th, AUGUST, 2021 @ SIDDIPET, TELANGANA
ABOUT COMPANY :
Jodas is a Global, specialty, innovation driven, emerging, generic pharmaceutical company, that is asserting itself among the world’s foremost pharmaceutical companies. We began our journey of growth in the year 2006 in India, and today Jodas is a modern, research driven organization that has quality and affordability at the heart of its activities.
Jodas focuses its operations on four speciality therapeutic segments:
· Anti Infectives (Injectables & Orals)
· Anti Cancer (Injectables & Orals)
· Contrast Media – Injectables
· Critical Care (Injectables & Orals)
Our dedicated team of healthcare professionals strives to bring specialty, high-quality, effective and affordable generic formulations to the market, touching millions of lives with good health.
Jodas has 40+ approved products in targeted emerging markets with State-of-the-art world-class manufacturing facilities and has successfully commercialized 7 million Injectables in the year 2014, with unparalleled customer satisfaction.
Focused to grow further in Emerging markets. The future endeavor is to be a Global generic player in highly regulated markets. We are committed to be “ONE STEP BETTER”, to fulfill the unmet medical needs of the healthcare community around the Globe with branded generic formulations of uncompromising quality.
Jodas has constantly upped the benchmark in uncompromising quality, with a pulse on rapidly changing innovation to commercialization landscape through our selection of a product range of affordable medicines and speed-to-the-market, along with our partners and Global supply chain.
We continuously evolve our business focus with a customer–centered portfolio of niche and technologically challenging products from specialty and therapeutic segments.
Our continuous focus on innovation and quality drives us to fulfill the unmet medical needs of the healthcare community and make the dreams of millions of people across the world come true with much needed medicines at an affordable value.
For more updates follow
To get global pharma news updates in whatsapp please
AUROBINDO PHARMA LTD HIRING CANDIDATES FOR TTD (TECHNOLOGY TRANSFER@ NAIDUPETA , NELLORE
ABOUT COMPANY :
Founded in 1986 by Mr. P. V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry.
Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and anti-biotics, among others.
VACANCY DETAILS :
Send Resumes Who are willing to relocate Nayudupeta Only
Send RESUMES On and before 04/08/2021
COMPANY : Aurobindo Pharma Ltd
JOB LOCATION : Nayudupeta , Nellore (Dt), Andra Pradesh
DEVISON : Formulation
DEPARTMENTS: TTD (TECHNOLOGY TRANSFER)
Designation : Executive
QUALIFICATION : B.Pharm/ M.Pharm
EXPERIENCE : Should have minimum experience of 2-7 years.
For more updates follow
To get global pharma news updates in whatsapp please
Sunday 1 August 2021
TORRENT PHARMA WALK IN INTERVIEW ON 08th, AUGUST, 2021 @ VAPI, GUJARAT
Torrent Pharma, the flagship Company of Torrent Group is one of the leading pharma companies of the Country. The Company was a pioneer in initiating the concept of niche marketing in India and and today is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.
Torrent Pharma's competitive advantage stems from the world-class manufacturing facilities, advanced R & D capabilities, extensive domestic network and a widespread global presence in over 40 countries.
The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceutical business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market.
Torrent Pharma started international acquisitions in 2005 with 90 year old Heumann from Pfizer to enter the German market. Later on purchased ANDA of Minocycline from Ranbaxy for the US Market in 2015.
In January 2018, Torrent also acquired Bio-Pharm, Inc. (BPI) a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA, which also included a US FDA registered manufacturing facility.
Torrent Pharma is committed towards “not just healthcare but lifecare.”
For more updates follow
To get global pharma news updates in whatsapp please
SUN PHARMACEUTICAL INDUSTRIES LTD WALK IN INTERVIEW ON 4th, AUGUST, 2021 @ DAHEJ, BHARUCH, GUJARAT
ABOUT COMPANY :
Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the fourth largest specialty generic pharmaceutical company in the world with global revenues of over US$ 4.5 billion. Supported by more than 40 manufacturing facilities, we provide high-quality, affordable medicines, trusted by healthcare professionals and patients, to more than 100 countries across the globe.
We manufacture and market a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates. Our broad portfolio of more than 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids.
Every year, we sell over 30 billion doses covering neuro-psychiatry, cardiology, gastroenterology, anti-infectives, diabetology, oncology, ophthalmology, dermatology, urology, nephrology and respiratory among others.
The first among Indian pharmaceutical companies to realise and embrace the importance of investing in research, we invest up to 7-8% of our global revenues into Research and Development (R&D) every year.
Our core strength lies in our ability to excel in developing generics and technologically complex products backed by our dedicated teams in formulations, process chemistry, and analytical development.
Our capabilities extend beyond the development of differentiated products, including liposomal products, inhalers, lyophilized injections, nasal sprays, and controlled release dosage forms.
Our R&D is led by a strong team of more than 2000 scientists.
From humble beginnings in 1983, Sun Pharma has grown to become one of the largest generic pharmaceutical companies worldwide. We are the largest pharmaceutical company in India.
In the US, we are among the top 10 generic pharmaceutical companies and are ranked second by prescriptions in the generic dermatology market.
We are the largest Indian company in emerging markets with a presence in over 80 markets. Brazil, Mexico, Russia, Romania and South Africa are some of our key emerging markets.
We are present across all major markets in Western Europe, Canada, Australia, New Zealand, Japan and China among others.
Our presence in emerging markets and the developing world enables our teams to cross-sell and build brands with ease.
For more updates follow
To get global pharma news updates in whatsapp please
SAI LIFE SCIENCES WALK IN INTERVIEW ON 7th, AUGUST, 2021 @ HYDERABAD
ABOUT COMPANY :
Sai Life Sciences is one of India’s fastest growing Contract Research, Development & Manufacturing Organizations. As a pure-play, full-service CRO-CDMO, we work with over a 100 global innovator pharma and biotech companies to accelerate the discovery, development, and commercialisation of their NCE small molecule programmes.
Over the past two decades, Sai Life Sciences has served a diverse set of programmes, consistently delivering value based on its quality and responsiveness. Today, it has over 2000 employees across its facilities in India, UK and USA.
At Sai Life Sciences, we deliver scientific expertise with a greater purpose – to impact tomorrow’s healthcare by creating medicines for today’s incurable maladies. We work with innovator pharma and biotech companies to accelerate the discovery, development and manufacture of complex small molecules for a healthier tomorrow. Our Vision is to support our global innovator partners bring 25 new medicines to life by 2025. And we are well on that journey.
For more updates follow
To get global pharma news updates in whatsapp please
AMNEAL PHARMACEUTICALS PVT LTD WALK IN INTERVIEW ON 07th AUGUST, 2021 @ AHMEDABAD
ABOUT COMPANY :
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Together, our team is working to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.
Today’s healthcare environment requires a new approach and new ideas. While staying true to our reputation for quality, service and value, we are reinventing our processes, our playbook and our creative partnerships. We are focused on delivering outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrow’s health challenges.
Our leadership and global colleagues are deeply experienced and forward-thinking. We have the capabilities, scale and resources for growth and success. We are nimble and determined. We are Amneal and We make healthy possible.
For more updates follow
To get global pharma news updates in whatsapp please
PFIZER WALK IN INTERVIEW FOR VIZAG PLANT ON 8th, AUGUST, 2021 @ AHMEDABAD
ABOUT COMPANY :
The pursuit of delivering breakthroughs is basic to Pfizer's culture. It shapes our strategy, defines our purpose, and governs every facet of our operations -- from research and development (R&D) that leads to pharmaceutical inventions, to the transfer of knowledge to patients and providers, to the way we respond to the changing marketplace.
Pfizer scientists have produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections. And today we're taking on some of the world's most difficult diseases, including cancer, arthritis, and osteoporosis.
Pfizer Limited was listed on the Indian stock exchange in 1966. Today, the company has over one lac shareholders in India. With annual sales of over Rs. 2,000 crores, it is the fourth largest multinational pharmaceutical company in India. The Company has a portfolio of over 150 products across 15 therapeutic areas.
Its top brands include Prevenar 13, Lyrica, Corex – DX, Dolonex, Enbrel, Becosules, Gelusil and Folvite among others. In addition to its commercial operations, Pfizer Limited also operates a state-of-the-art, award-winning manufacturing facility in Goa that produces more than a billion tablets annually.
The Company employs 2,631 colleagues, and is committed to providing therapies to prevent and treat some of the most critical diseases that impact public health in India today.
For more updates follow
To get global pharma news updates in whatsapp please
INTAS PHARMACEUTICALS LTD WALK IN INTERVIEW ON 08th, AUGUST, 2021 @ AHMEDABAD
ABOUT COMPANY :
Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas is committed to challenging the unmet medical and societal needs through a comprehensive pharmaceutical value chain spanning across the world.
Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide with robust sales, marketing and distribution infrastructure in markets like North America, Europe, Central & Latin America, Asia-Pacific as well as CIS and MENA countries. Intas’ remarkable success in North America and European operations have helped us emerge as a global brand in the world’s largest pharmaceutical markets.
Every Intas product and service is a testament to its uncompromising quality standards. All products are manufactured in facilities that are approved by major global regulatory agencies including the USFDA, MHRA, EMA, TGA, MCC, ANVISA and more. Today, a segment-leading pipeline and strong in-house development capabilities allow Intas to compete with some of the biggest portfolios in the industry. Intas is currently investing in a higher barrier to entry developments such as Biosimilar and New Chemical Entities and is set to continue raising the bar of healthcare excellence, globally in the near future.
Intas believes in empowering people. Therefore, to fulfil its corporate vision, Intas aims to acquire and retain the best talent across the industry to fully leverage the diversity of respective markets they operate in.
For more updates follow
To get global pharma news updates in whatsapp please
Subscribe to:
Posts (Atom)